drugset

drugset / Trial / NCT01256372

An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery

NCT01256372 ↗

Phase 2 Completed 77 enrolled Action Pharma A/S

RandomizedParallel-groupTriple-blindPrevention

Summary

This study investigates the effect of two dose-levels of AP214 on the prevention of (acute) kidney injury after cardiac surgery.

Timeline

Start: 2010-10
Primary completion: 2011-06
Completion: 2011-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MODIMELANOTIDE	Protein / enzyme biologic	—	—

Indications